Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Mol Cancer Res. 2015 Feb 27;13(5):863–869. doi: 10.1158/1541-7786.MCR-14-0709

Figure 5.

Figure 5

Loss of Trp53 results in PDAC formation

Animals receiving Kras-shRNAControl-PDCs did not develop tumors. Animals injected with Kras-shRNATrp53 develop tumors and die due to their tumor burden. A) and B) Gross anatomy shows tumor growth within the anatomical site of injection and histology confirms tumor growth (magnification 50× and 200×).